Raymond P. Perez

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

Anne F. Schott, Lori J. Goldstein, Massimo Cristofanilli et al. · Clinical Cancer Research · 2017 · 240 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Kathleen N. Moore, Lainie P. Martin, David M. O’Malley et al. · Journal of Clinical Oncology · 2017 · 219 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 1 dose‐escalation study of mirvetuximab soravtansine (<scp>IMGN853</scp>), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors

Kathleen N. Moore, Hossein Borghaei, David M. O’Malley et al. · Cancer · 2017 · 141 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Lainie P. Martin, Jason Konner, Kathleen N. Moore et al. · Gynecologic Oncology · 2017 · 139 citations · Full text

Medicine, Oncology, Pharmacology +13

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Lori J. Goldstein, Raymond P. Perez, Denise A. Yardley et al. · Breast Cancer Research · 2020 · 137 citations · Full text

Medicine, Oncology, Pharmacology +17